The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries

Findings raise important policy concerns. Availability of inhaled corticosteroids is poor; many EMLs are not updated; IRPs can be misleading; health systems and patients are paying more than necessary for asthma medicines, which are unaffordable for many patients in many countries. </AbstractSection> Copyright Springer International Publishing Switzerland 2013

MoreLess

Year of publication:	2013
Authors:	Babar, Zaheer-Ud-Din ; Lessing, Charon ; Mace, Cécile ; Bissell, Karen
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 31.2013, 11, p. 1063-1082
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001618